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THE ROLE AND THERAPEUTIC POTENTIAL OF EXTRACELLULAR 
VESICLES IN ATHEROSCLEROSIS  
NHI NGUYEN  
ABSTRACT 
 Atherosclerosis, the pathophysiology of many cardiovascular diseases (CVD), is a 
chronic inflammatory process caused by the sustained accumulation of cholesterol, 
followed by endothelial dysfunction, and the resulting vascular inflammation. The 
established treatment for atherosclerosis, to date, involves the use of statins. These 
medications are hydroxymethylglutaryl coenzyme A reductase (HMG-CoA) inhibitors and 
lower the levels of by inhibiting HMG-CoA, a rate limiting step in the biosynthesis of 
cholesterol. Statin therapy varies in effectiveness based on dosage and individual 
differences, making effective treatment of patients challenging. More recently, 
extracellular vesicles (EVs) have emerged as a promising field in cardiovascular research. 
Once thought of as “platelet dust,” EVs are now recognized for their potential as 
therapeutic targets and tools. In this review, a comprehensive characterization of EVs is 
provided to explain how EVs are involved in normal physiological function and 
pathological processes of atherosclerosis. Evidence supports a model where EVs 
participate in the initiation and progression of atherosclerosis and may also be used as a 
delivery tool in disease therapy. Currently, cell-derived EVs can be therapeutic agents in 
animal models, an effective tool in gene therapy, or a drug delivery vehicle. Future 
experiments enhancing the therapeutic potential of EVs promise to deepen our 
understanding of EV-based therapy for atherosclerosis precision medicine. 
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CHAPTER 1 
INTRODUCTION 
Pathophysiology of Cardiovascular Disease 
 Cardiovascular disease (CVD) is a term used to describe a group of heart-related 
pathologies which include coronary heart disease, cerebrovascular disease, peripheral 
arterial disease, congenital heart disease, and deep vein thrombosis (Stewart, Mammathan, 
& Wilkinson, 2017). Although advances in research and therapies emerge frequently, CVD 
remains the major leading cause of morbidity and death worldwide (Amosse, Martinez, & 
Le Lay, 2017). In fact, about one third of global deaths are caused by CVDs (Amosse, 
Martinez, & Le Lay, 2017; Stewart, Manmathan, & Wilkinson, 2017). Many factors 
contribute to the increasing incidence and prevalence of CVDs, making the prevention and 
treatment multifaceted. These factors include hypertension, hyperlipidemia, diabetes, 
tobacco use, and physical inactivity (Benjamin et al., 2018; Thayer, Yamamoto, & 
Brosschot, 2010). In addition to these risk factors, the rising age of the population further 
exacerbates the burden of CVD, creating a challenge for current and future physicians to 
provide effective treatments (Dimmeler, 2011).  
Atherosclerosis is a chronic inflammatory condition wherein lipids and cholesterol 
accumulate in the blood vessels, causing them to narrow and harden (Bergheanu, Bodde, 
& Jukema, 2017; Scott, 2004). Normal blood vessels in mammals have three main layers: 
the tunica intima, tunica media, and tunica adventitia (Camare, Pucelle, Nègre-Salvayre, 
& Salvayre, 2017). The tunica intima is the innermost layer made up of endothelial cells 
(ECs). This layer comes into contact with flowing blood and undergoes intimal thickening 
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in the early stages of atherosclerosis. The tunica media is the middle layer made up of 
smooth muscle cells (SMCs) and extracellular substances. The tunica adventitia is the 
outermost layer of the blood vessel and is made up of fibroblasts and loose connective 
tissue. This loose connective tissue contains a vascular supply called the vasa vasorum that 
supply nutrients to blood vessels (Camare, Pucelle, Nègre-Salvayre, & Salvayre, 2017).  
Atherosclerosis results from multiple processes (steps summarized in Figure 1) 
beginning with a chronic accumulation of cholesterol, followed by endothelial dysfunction, 
and the resulting vascular inflammation (Hansson, 2005). Hyperlipidemia initiates the 
development of atherosclerosis by allowing apolipoprotein B (ApoB)-containing 
lipoproteins like cholesterol-rich low density lipoprotein (LDL) to leave the circulatory 
system and enter susceptible arterial walls (Bergheanu, Bodde, & Jukema, 2017; Ferrence 
et al., 2017; Linton et al., 2000; Rafieian-Kopaei, Setorki, Doudi, Baradaran & Nasri, 
2014). Vulnerable sites include areas of vasculature that have turbulent flow such as near 
branch points, as well as by the abdominal aorta, coronary arteries, and iliofemoral arteries 
(Bentzon, Otsuka, Virmani, & Falk, 2014; Zmyslowski & Szterk, 2017).  
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Figure 1: Steps in atherosclerosis pathway. Atherosclerosis is a consequence of chronic 
accumulation of cholesterol-rich low-density lipoprotein, followed by endothelial 
dysfunction, and the activation of vascular inflammatory cascade. These mechanistic steps 
lead to clinical events of atherosclerosis. LDL: low-density lipoprotein, ECM-PG: 
extracellular matrix proteoglycan, SM: smooth muscle. Figure adapted from (Aziz & 
Yadav, 2016). 
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LDL is one of five major groups of lipoproteins that transport lipids and cholesterol 
in the body (Ferrence et al., 2017). LDL is made up of a core of triglycerides and cholesterol 
ester molecules surrounded by a variety of phospholipids, such as phosphatidylcholine, 
lysophosphatidylcholine, and sphingomyelin, and apoB-100 (Esterbauer, Gebicki, Puhl, & 
Jurgens, 1992; Hevonoja et al., 2000; Lund-Katz & Phillips, 1986). LDL enters arterial 
walls to reach the subendothelial space through transcytosis, a process that involves 
receptor-mediated endocytosis on the apical end of ECs and exocytosis on the basolateral 
end (Goldstein & Brown, 2009; Mundi et al., 2018). LDL binds to LDL receptors located 
in clathrin-coated pits on the surface of ECs, creating vesicles that become internalized and 
shuttled through the ECs (Anderson, Goldstein, & Brown, 1976; Anderson, Brown, & 
Goldstein, 1977; Brown & Goldstein, 1976; Pearse, 1976; Mundi et al., 2018). At the 
basolateral membrane of ECs, the LDL-containing vesicles fuse with the membrane, 
causing the release of LDL into the subendothelial space (Mundi et al., 2018). Here, LDLs 
are modified by specific enzymes to become oxidized LDL (oxLDL), enabling a 
proinflammatory function and causing an inflammatory cascade (Bentzon, Otsuka, 
Virmani, & Falk, 2014; Mundi et al., 2018).  
As atherosclerosis progresses, continued LDL accumulation and modification leads 
to the increased permeability of the tunica intima contributing to increased accumulation 
of LDL and immune cells at the site (Bentzon, Otsuka, Virmani, & Falk, 2014). Monocytes 
can diapedese into the arterial wall, causing more inflammatory cells to flood to the area 
as well as initiate the migration of SMCs into the tunica intima leading to intimal thickening 
(Bentzon, Otsuka, Virmani, & Falk, 2014). Upon entry into the tunica intima, monocytes 
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acquire features of macrophages and engulf LDL in multiple small inclusions to create 
foam cells (Bergheanu, Bodde, & Jukema, 2017; Insull, 2009; Stoll & Bendszus, 2006). 
Once foam cells accumulate in the tunica intima, the plaque is referred to as fatty streaks 
or intimal xanthomas (Aziz & Yadav, 2016; Bentzon, Otsuka, Virmani, & Falk, 2014; 
Insull, 2009).  
Many intimal fatty streaks may resolve later in life (Otsuka, Yasuda, Noguchi, & 
Ishibashi-Ueda, 2016) but those at vulnerable sites may develop further as progressive 
atherosclerotic plaques (Kolodgie et al., 2007). This is characterized by a continued 
accumulation of lipid-rich substances and foam cells, leading to a progressively thicker 
plaque. At this stage, the plaque has pathological intimal thickening (Bentzon, Otsuka, 
Virmani, & Falk, 2014; Kolodgie et al., 2007). The atherosclerotic plaque can become 
necrotic as macrophages invade the area. The presence of a necrotic core in the plaque 
characterizes the atherosclerotic lesion as fibrous cap atheroma or fibroatheroma (Aziz & 
Yadav, 2016; Bentzon, Otsuka, Virmani, & Falk, 2014). Fibrous plaques can become thin 
cap fibroatheroma, which are more likely to rupture. The migrated SMCs surrounding the 
lesion produces more collagen, causing atherosclerotic plaques to be calcified. 
Calcification contributes to the increase in size of atherosclerotic plaques and can cause an 
impediment in blood flow (Bentzon, Otsuka, Virmani, & Falk, 2014; Crowther, 2005; 
Insull, 2009). The stages of atherosclerotic plaque development and progression are shown 
below (Table 1).  
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Table 1: Atherosclerotic plaques in disease progression. The stages of atherosclerotic 
plaques based on morphological descriptions as the atherosclerotic lesion develops over 
time. SMCs: smooth muscle cells. Table adapted from (Aziz & Yadav, 2016). 
 
Atherosclerosis Development and Progression  
Inflammation Induced by Endothelial Dysfunction 
At vulnerable areas in blood vessels, disturbances in blood flow can cause turbulent 
blood flow and shear stress, the forces of flowing blood, on the walls (Chiu & Chien, 2011). 
Typically, low shear stress, or shear stress with changing directions of flow, can be found 
in turbulent blood flow and promotes changes in ECs (Paszkowiak & Dardik, 2003). As a 
result, ECs lining blood vessels respond by increasing the production of nitric oxide (NO) 
which participates in regulating vascular tone (Zmysłowski & Szterk, 2017). NO is 
produced by endothelium nitric oxide synthase (eNOS) and can immediately reduce the 
shear stress on blood vessels (Napoli et al., 2006; Zmysłowski & Szterk, 2017). If this shear 
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stress has not been addressed by NO sufficiently, the nuclear factor (NF)-κB pathway, a 
negative regulator of eNOS (Lee et al., 2014), will be initiated in an inflammatory response 
(Zmysłowski & Szterk, 2017). The disturbances in blood flow also causes alterations in 
the tight junctions between ECs, allowing for the movement of LDL and immune cells into 
the blood vessel.  
LDL in the subendothelial space can be modified through enzymatic reactions such 
as oxidation, acylation, lipolysis, proteolysis, or aggregation (Kokkonen & Kovanen, 1989; 
Oorni, Hakala, Annila, Ala-Korpela & Kovanen, 1998; Oorni, Pentikainen, Ala-Korpela, 
& Kovanen, 2000). The main reaction of interest is oxidation of LDL through the creation 
of reactive oxygen species (ROS), creating a minimally oxidized LDL (Maiolino et al., 
2013; Zmysłowski & Szterk, 2017). This minimally oxidized LDL undergoes more 
oxidation reactions to form oxLDL (Figure 2). The oxidation of LDLs causes an increased 
inflammatory response in addition to retention of LDLs. Moreover, oxLDL increases the 
activity of S-adenosylmethionine-dependent methyltransferases, an enzyme that leads to 
the inhibition of (eNOS) (Zmysłowski & Szterk, 2017). As a result of eNOS inhibition, the 
inflammatory cascade continues and more LDL accumulate in the tunica intima, 
contributing to the progression of atherosclerotic plaques (Maiolino et al., 2013).  
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Figure 2: Oxidation of LDLs. After migrating into the walls of blood vessels, LDL 
particles undergo oxidation reactions to become minimally oxidized LDL which becomes 
highly oxidized LDL. Figure adapted from (Zmysłowski & Szterk, 2017).  
 
Necrotic Core and Thin Cap Fibroatheroma Formation 
 As LDL and inflammatory cells accumulate in the arterial wall, the atherosclerotic 
lesion thickens towards the lumen of the blood vessel. Due to LDL retention, monocytes 
tightly adhere to ECs and diapedese into the subendothelial space, a mechanism that most 
likely plays a role in amplifying the LDL accumulation and preventing atherosclerotic 
lesions from resolving (Moore & Tabas, 2011). Monocytes differentiate into macrophages 
or cells with dendritic cell features. These macrophages and dendritic-like cells ingest 
oxidized LDL through scavenger receptors, causing them to have lipid droplets in the 
cytoplasm and turning them into foam cells (Moore & Tabas, 2011). As a result of 
prolonged stress, foam cells undergo apoptosis but are not cleared from the area leading to 
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secondary necrosis and the eventual development of a necrotic core in the atherosclerotic 
lesion (Bentzon, Otsuka, Virmani, & Falk, 2014; Moore & Tabas, 2011).  
 Experiments with ApoE-/-, a widely used murine model for atherosclerosis, provide 
evidence that macrophage apoptosis is involved in the development of a necrotic core 
(Gautier, 2009). ApoE is a ligand for ApoB and LDL receptors and is involved in their 
clearance (Sasso et al., 2016). Mice deficient in ApoE, created through gene targeting 
(Zhang, Reddick, Piedrahita, & Maeda, 1992), result in disturbed lipoprotein clearance and 
hypercholesterolemia (Sasso et al., 2016; Zhang, Reddick, Piedrahita, & Maeda, 1992). 
Researchers investigating the role of macrophage apoptosis in the formation of a necrotic 
core genetically engineered the start of apoptosis or protected against apoptosis in ApoE-/- 
mice (Gautier et al., 2009). By doing so, they showed that macrophage apoptosis inhibition 
can prevent further recruitment of macrophages to the area, preventing the increase of 
inflammatory response. In direct contrast, through the induction of macrophage apoptosis 
in mice, the development and progression of necrotic core within the atherosclerotic lesion 
increased (Gautier et al., 2009).  
 In addition to necrotic core formation, macrophages are involved in the processes 
that lead to the development of a thin cap fibroatheroma. A thinning fibrous plaque can be 
caused by a decrease in the synthesis of collagen by the SMCs within blood vessels (Moore 
& Tabas, 2011). Macrophages can decrease collagen synthesis by secreting less 
transforming growth factor (TGF)-b, a necessary inducer of collagen synthesis. In doing 
so, a thin cap fibroatheroma can develop (Boyle, Weissberg, & Bennett, 2003). 
Atherosclerotic plaques that are prone to rupture have increased SMC apoptosis and a 
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decreased number of SMCs, likely due to macrophages (Moore & Tabas, 2011). 
Macrophages that accumulate within the blood vessel trigger the death of SMCs through 
the activation of the Fas signaling pathway for apoptosis or by secreting tumor necrosis 
factor (TNF)-α or NO, both of which are pro-apoptotic (Boyle, Weissberg, & Bennett, 
2003). Macrophages can also release matrix metalloproteinases which are enzymes that 
can degrade collagen and allow the movement of SMCs (Vacek et al., 2015).      
Plaque Angiogenesis 
 In the progression of atherosclerotic lesions, angiogenesis is an important process 
to help stabilize the plaque and sustain the chronic inflammation (Pant, Deshmukh, & 
Mehta, 2013). Neovessels grow into the progressing atherosclerotic lesion, creating a 
pathway for more monocytes to invade the intima and growing plaque. This increased 
monocyte infiltration causes plaques to become unstable, increasing the risk of plaque 
rupture (Rautou et al., 2011). Typically, these neovessels are fragile since they lack 
supporting cells (Pant, Deshmukh, & Mehta, 2013). As a result, the new vessels can be 
leaky, allowing the escape of plasma proteins and red blood cells. This hemorrhaging 
commonly occurs in fibroatheromas and can enlarge the necrotic core and contribute to the 
sustained inflammation (Bentzom, Otsuka, Virmani, & Falk, 2014). 
 Angiogenesis in atherosclerotic lesions generally occurs through sprouting 
angiogenesis from the vasa vasorum of the tunica adventitia (Mathur, Pant, Deshmukh, 
Khattoor, & Mehta, 2017). The growth of these neovessels occurs through the release of 
angiogenic substances like vascular endothelial growth factor (VEGF) and NO (Mathur, 
Pant, Deshmukh, Khattoor, & Mehta, 2017). VEGF and NO causes vasodilation, allowing 
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for the migration of ECs and the eventual formation of an angiogenic bud (Camare, Pucelle, 
Negre-Salvayre, & Salvayre, 2017). ECs leading this bud formation are referred to as tip 
cells. Tip cells are named for their migratory function, enabled by their filipodia which are 
projections that extend from cell membranes that allow for the movement of cells (Mattila 
& Lappalainen, 2008). The filipodia of tip cells are rich in VEGF receptor (VEGFR)-2 
which directs sprouting of neovessels (Camare, Pucelle, Negre-Salvayre, & Salvayre, 
2017; de Vries & Quax, 2016). Tip cells also secrete enzymes that degrade the extracellular 
matrix allowing for the expansion of this new bud (Blanco & Gerhardt, 2013; Camare, 
Pucelle, Negre-Salvayre, & Salvayre, 2017). ECs that follow the migration of tip cells are 
referred to as stalk cells and these cells support the growth of the angiogenic bud (Blanco 
& Gerhardt, 2013; Camare, Pucelle, Negre-Salvayre, & Salvayre, 2017). As tip cells and 
the trailing stalk cells migrate, tip cells will meet with other migrating tip cells. Once this 
occurs, the buds join together and a vascular lumen is created (Camare, Pucelle, Negre-
Salvayre, & Salvayre, 2017; Mathur, Pant, Deshmukh, Khattoor, & Mehta, 2017; Pant, 
Deshmukh, & Mehta, 2013). The neovessel becomes stabilized as it interacts with the 
surrounding SMCs. The growth of new vascular vessels allow the atherosclerotic plaques 
to be nourished and progress.  
Plaque Rupture and Thrombosis 
 Atherosclerotic plaques are dangerous in that they can grow to a size that obstructs 
blood flow; however, they rarely cause death unless the plaques rupture and result in 
thrombosis (Falk, Nakano, Bentzon, Finn, & Virmani, 2013). For example, thrombus 
formation can result in sudden coronary death (Bentzom, Otsuka, Virmani, & Falk, 2014; 
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Davies, 2000). The rupture and erosion of atherosclerotic plaques are the most common 
causes of thrombosis (Davies, 2000). Plaque rupture and plaque erosions occur where the 
fibrous cap is the thinnest; in other words thin cap fibroatheromas are the most vulnerable. 
Rupturing of an atherosclerotic plaque occurs when a gap in the plaque allows the necrotic 
core to be exposed to the luminal blood. Erosion is a term used when calcified material 
from a fibrous plaque is found within the lumen of a blood vessel but no evidence of a 
plaque rupture can be determined microscopically (Bentzom, Otsuka, Virmani, & Falk, 
2014; Virmani, Kolodgie, Burke, Farb, & Schwartz, 2000). Plaque rupture may be 
spontaneous or be triggered by physiological events that activate the sympathetic nervous 
system (Bentzom, Otsuka, Virmani, & Falk, 2014; Davies, 2000). Subsequently, ruptured 
plaques can cause thrombosis. The plaque themselves may heal and the thrombus may 
resolve or travel to other sites and disrupt the flow of blood (Figure 3). The mechanisms 
of plaque erosions are less well understood and require more research.  
 
Figure 3: Atherosclerotic plaque rupture. Thin cap fibroatheromas can rupture after 
being triggered by physiological stimuli. As a result, a thrombus can form within the lumen 
of the blood vessel. This may be non-fatal or fatal if migratory and obstruct blood flow in 
an important site. The atherosclerotic plaque will heal, leaving the lumen narrower. Figure 
taken from (Bentzom, Otsuka, Virmani, & Falk, 2014).  
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 Thrombosis is another stage in atherosclerosis progression that requires more 
discussion since it may cause the fatality seen in patients with cardiovascular issues. Once 
an atherosclerotic plaque ruptures, platelets circulating in the blood adhere to the thrombus 
(Badimon & Vilahur, 2014; Kaushansky, 2005). This adhesion is initially mediated by the 
interaction between platelet glycoprotein Ibα and von Willebrand factor (Hou et al., 2015). 
This interaction is not irreversible but platelet collagen receptors integrin α2β1 and 
immunoglobulin help maintain a strong platelet aggregate with the thrombus (Badimon & 
Vilahur, 2014; Hou et al., 2015). In atherosclerotic plaques, tissue factor (TF) expressed in 
foam cells trigger the formation of thrombin (Badimon & Vilahur, 2014; Hou et al., 2015). 
When TF is exposed to flowing blood subsequent to plaque rupture, the coagulation 
cascade begins. TF interacts with various cofactors that leads to the formation of thrombin 
from prothrombin (Freynhofer, Bruno, Wojta, & Huber, 2012). Thrombin cleaves 
fibrinogen to fibrin, further stabilizing the thrombus (Freynhofer, Bruno, Wojta, & Huber, 
2012). This thrombus can cause stable angina or lead to infarctions at a distant site (Falk, 
Nakano, Bentzon, Finn, & Virmani, 2013).  
Calcification in Atherosclerotic Plaques  
 In atherosclerosis, the connective tissue in the tunica adventitia layer may become 
involved in plaque progression. The loose connective tissue may gradually be replaced by 
collagen-rich fibrous tissue (Bentzom, Otsuka, Virmani, & Falk, 2014). Over time, 
calcification or the process of calcium deposition in vasculature can occur (Albanese, 
Khan, Barratt, Al-Kindi, & Schwertani, 2018). Calcification in atherosclerosis begins with 
microcalcifications, which can occur from macrophage apoptosis in thin cap 
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fibroatheromas (Badimon & Vilahur, 2014; Maldonado et al., 2012; Roijers et al., 2011). 
The microcalcifications form larger aggregates that can involve the necrotic core. 
Calcification can extend into the matrix of collagen surrounding the necrotic core, leading 
to the formation of calcified sheets or plates (Mori et al., 2016). Once these calcified plates 
form, they can fracture leading to nodular calcification and fibrin deposition. These nodules 
can extend into the lumen of the blood vessels and can become thrombotic (Albanese, 
Khan, Barratt, Al-Kindi, & Schwertani, 2018; Mori et al., 2016). Calcifications are very 
common in atherosclerotic plaques in later stages. The necrotic core and the surrounding 
matrix can become completely calcified, making up most of the atherosclerotic plaque 
volume (Bentzom, Otsuka, Virmani, & Falk, 2014).  
 
Current Treatment for Atherosclerosis and Obstacles  
Many pharmacological treatments have been discovered and several biological 
therapies are pursued to treat and prevent atherosclerosis and CVD. The most established 
treatment for atherosclerosis involves lowering the elevated levels of LDL in the blood 
(Scott, 2004). The first-line therapeutic intervention involves lifestyle changes such as 
adopting a low cholesterol diet, increased physical activity, and smoking cessation (Lewis, 
2009). Although this can be accomplished with the help of primary care physicians and 
registered dieticians, many patients cannot achieve their target goal of cholesterol levels 
with just lifestyle changes alone (Lewis, 2009). Often, medications used for lipid-lowering 
therapies are prescribed in addition to the aforementioned modified lifestyle factors. The 
primary medication prescribed for reducing lipid levels is hydroxymethylglutaryl 
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coenzyme A reductase (HMG-CoA) inhibitors, also known as statins (Lewis, 2009; 
Ramukumar, Raghunath, & Raghunath, 2016; Riccioni & Sblendorio, 2012). Statins help 
lower cholesterol levels by inhibiting HMG-CoA, a rate limiting step in the biosynthesis 
of cholesterol (Ramukumar, Raghunath, & Raghunath, 2016). Statins are well-tolerated by 
patients and are considered the first-line pharmacological treatment to combat 
hyperlipidemia (Lewis, 2009). In addition to its lipid-reducing abilities, statins also display 
anti-inflammatory effects; treated patients have fewer macrophages and inflammatory cells 
which could contribute to plaque stabilization (Cortellaro et al., 2002; Crisby et al., 2001; 
Riccioni & Sblendorio, 2012). 
Despite being the established form of pharmacological treatment for 
atherosclerosis, lowering LDL levels only decreases the risk of atherosclerotic 
cardiovascular events by 30% (Scott, 2004). This may be due to the long incubation period 
of chronic inflammation in atherosclerosis development. Moreover, there is a variety of 
responses from patients who take different types of statins at different approved dosages. 
If individual differences are accounted for, certain pharmacological therapies for 
atherosclerosis that work for most of the population are ineffective for about 30% to 60% 
of patients (Lee, Flammer, Lerman, & Lerman, 2012). Even statins, the primary medication 
prescribed to help lower LDL levels, vary in effectiveness based on the medication and 
dosage (Table 2).  
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Table 2: Percent decrease in plasma LDL for six available statins. Approved dosages 
for six different statins to treat hyperlipidemia have varying degrees of effectiveness in 
lowering LDL levels. This highlights the need to consider other treatments for 
atherosclerosis. Table adapted from (Chong, Seeger, & Franklin, 2001).  
 
Physicians and scientists must consider different approaches and therapies to 
improve clinical outcomes for patients at risk for atherosclerotic events. The current 
standard therapy to lower cardiovascular morbidity and mortality involves a traditional 
reductionist, one size fits most, approach where patient input to physician and evidence 
based medicine are incorporated (Leopold & Loscalzo, 2018). This approach begins with 
patient description of their symptoms followed by physician assessment and 
recommendation of medications that improve symptoms in a small number of patients 
(Leopold & Loscalzo, 2018). Although this method reduces the symptoms and slows 
disease progression of most patients, it fails to improve symptoms in a subgroup of the 
population and fails to address the complexity of atherosclerosis that does not have a single 
root cause (Leopold & Loscalzo, 2018).  
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Considering Precision Medicine for Atherosclerosis Therapy  
Since atherosclerosis is multifaceted, its treatment needs the same complexity and 
intricacies. The standard treatment for atherosclerosis, to date, involves pharmacological 
treatments to lower LDL levels such as statin therapy (Bergheanu, Bodde, & Jukema, 
2017). To improve patient outcomes, clinicians should consider precision medicine for 
atherosclerosis therapy. Precision medicine has been strongly endorsed as technological 
advancements in genomics have been made in recent years (Lin, Long, Wang, Zheng, & 
Zhao, 2017). This field involves the use of individual data such as genetic information in 
addition to biomarkers to better treat patients based on their presentation of disease (Dainis 
& Ashley, 2018; Wang, Cho, Wong, Liu, 2017). Considering genetic information and 
appropriate biomarkers is important in precision medicine since they can be used in the 
diagnosis and treatment of disease (Charo & Taub, 2011; Lee, Flammer, Lerman, & 
Lerman, 2012; Wang, Cho, Wong, Liu, 2017).  
In recent years the field of extracellular vesicles (EVs) has expanded rapidly within 
CVD research and precision medicine (Dickhout and Koenen, 2018; Piffoux et al., 2018). 
EVs are heterogenous particles surrounded by phospholipid bilayers that are released in an 
evolutionarily conserved manner from both prokaryotic and eukaryotic cells (Gaceb, 
Martinez, Andriantsitohaina, 2014; Yanez-Mo et al., 2015). EVs were originally first 
reported by Chargaff and West (1946) and even two decades after, EVs were thought of as 
“platelet dust” (Gaceb, Martinez, Andriantsitohaina, 2014; Hafiane & Daskalopoulou, 
2018; Yanez-Mo et al., 2015). It was not until 2006 (Ratajczak et al., 2006) and 2007 
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(Valadi et al., 2007) when the discovery was made that EVs contained ribonucleic acid 
(RNA), driving scientific inquiry towards EVs being the mediators of cellular 
communication.  
EVs are found in all body fluids and can be released from various cell types during 
cellular activation (Dickhout & Koenen, 2018; Hafiane & Daskalopoulou, 2018). Their 
presence in many cellular environments imply they may have many functions in various 
physiological and pathological processes. EVs are heterogeneous in size, density, 
biogenesis, composition, and functions but the major importance of EVs may be their 
ability to communicate with other cells that are involved in inflammation and endothelial 
dysfunction (Hafiane & Daskalopoulou, 2018). The discussion of EVs will further our 
understanding of how these particles play a role in atherosclerosis. Moreover, 
understanding how EVs can be utilized will help advance the development of precision 
medicine for atherosclerosis treatment.  
 
Specific Aims 
 The specific aims of the following thesis are to: 
1. Review on the current literature on EVs. 
2. Discuss the associations of EVs in atherosclerosis and how EVs can be a 
potential biomarker for atherosclerosis.  
3. Explore the potential therapeutic potential (and limitations) of EVs in 
atherosclerosis. 
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CHAPTER 2 
PRECISION MEDICINE IN THE TREATMENT OF ATHEROSCLEROSIS  
What is Precision Medicine?  
Precision medicine, first introduced in the 1990s as personalized medicine, is a field 
that involves both clinicians and researchers using integrated technologies to understand 
the molecular mechanism of disease (Lee, Flammer, Lerman, & Lerman, 2012). Its 
introduction in medicine was meant to address the “one-size-fits-all” approach that has 
been adopted in disease therapy (Dainis & Ashley, 2018; Konig, Fuchs, Hansen, Mutius, 
& Kopp, 2017). Although many have rightly argued that medicine was intended to be 
precise (Seymour et al., 2017), the term precision medicine actually refers to the aspiration 
of incorporating multiple data sources from genomics, proteomics, metabolomics, and 
biomarkers to diagnose more accurately and approach treatment more individually (Dainis 
& Ashley, 2018; Lin, Long, Wang, Zheng, & Zhao, 2017; Lee, Flammer, Lerman, & 
Lerman, 2012). There are several goals of precision medicine including improved disease 
categorization, detection, and diagnosis as well as providing personalized therapies to delay 
disease onset and progression (Beckman & Lew, 2016; Dainis & Ashley, 2018).  
 
The Potential Role of EVs in Precision Medicine  
The concept of precision medicine is not new; frankly, it is inevitable in this era of 
scientific and technological advancements. Despite significant growth in precision 
medicine, not many clinical providers have incorporated it into CVD and atherosclerosis 
therapy (Lee, Flammer, Lerman, & Lerman, 2012). The study of EVs as a focus in CVD is 
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still relatively new (Dickhout & Koenen, 2018); therefore the interaction between EVs and 
precision medicine for atherosclerosis is in its infancy. Based on the current understanding 
of EVs, however, advances in EV research aligns with the goals of precision medicine and 
can potentially be applied to atherosclerosis therapy (Piffoux et al., 2018). One of the goals 
of precision medicine is to improve disease detection and diagnosis (Beckman & Lew, 
2016; Dainis & Ashley, 2018). EVs are released from cells in physiological and 
pathological processes in the body and have been correlated with disease development 
(Dickhout & Koenen, 2018; Piffoux et al., 2018). For instance EVs are released during 
endothelial dysfunction, a process that characterizes the early initiation of atherosclerosis 
(Dignat-George & Boulanger, 2011; Jansen, Nickenig, & Werner, 2017; Libby, 2001). If 
EVs can be appropriately measured and detected in the initiation of atherosclerosis, 
researchers may be able to better detect and diagnose atherosclerosis in the early stages.   
Another goal of precision medicine is to incorporate the use of biomarkers to 
monitor disease status (Piffoux et al., 2018). Several established reviews have examined 
whether EVs can be a potential accurate biomarker for CVD (Boulanger, Loyer, Rautou, 
& Amabile, 2017; Dickhout & Koenen, 2018; Sluijter et al., 2018; Thulin, Christersson, 
Alfredsson, & Siegbahn, 2016). Overall, researchers found changes in levels of EVs from 
different cellular origins in CVDs and other vascular diseases (Table 3). The structure of 
EVs, specifically the phospholipid bilayer surrounding the inner components, is of 
particular importance for EVs to be considered a potential biomarker (Tao, Guo, & Zhang, 
2018). Since membranes exists to protect the contents of EVs from the external 
environment, EVs maintain a biological stability without degradation in various body 
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fluids including blood, saliva, urine, and bile (Tao, Guo, & Zhang, 2018). Moreover, they 
are released by various cell types (Hafiane & Daskalopoulou, 2018) and may contain 
important information from their origin (Dickhout & Koenen, 2018). Although the current 
EV biomarker research show only correlations, its potential as a biomarker is considerable 
and will be discussed further.  
Table 3: EVs are involved in CVDs. EVs released from various cells are involved in CVD 
and other vascular diseases. EV: extracellular vesicle, CVD, cardiovascular disease. Table 
adapted from (Dickhout & Koenen, 2018). 
 
In addition to its potential diagnostic value, EV research aligns with the goal of 
precision medicine due to its therapeutic potential. Since EVs are derived from various 
cells and can communicate with other cells, EVs can be redirected and used for treatments 
in cell-based therapies. There are two options in using EVs as a therapeutic tool. One 
possibility is to target EVs as mediators of signaling pathways involved in CVD 
pathogenesis (Danielson & Das, 2014). Alternatively, EVs can be a tool to deliver drug 
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treatments (Danielson & Das, 2014). In this discussion, the focus will be on how EVs may 
be a delivery tool and a therapeutic agent. Further research on the role of EVs in CVD may 
provide novel therapeutic tools for future clinicians and researchers to combat this global 
public health concern.  
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CHAPTER 3 
CHARACTERISTICS OF EXTRACELLULAR VESICLES 
EV Classification  
 EVs are particles released from a variety of cells within the body (Gaceb, Martinez, 
Andriantsitohaina, 2014). Despite the growing field in EV research, there is no consensus 
on their nomenclature (Malloci et al., 2019). Currently, there are three main categories into 
which EVs are classified: apoptotic bodies, microvesicles (MVs), and exosomes (Figure 
4) (Malloci et al., 2019) . Apoptotic bodies are the largest subgroup of EVs and are released 
from cells undergoing apoptosis (Jansen, Nickenig, & Werner, 2017). MVs, smaller than 
apoptotic bodies, range from 100-1000 nanometers and are released directly from the cell 
membrane. In contrast, exosomes represent the smallest type of EVs being about 40-100 
nanometer in size (Danielson & Das, 2014; Jansen, Nickenig, & Werner, 2017). Exosomes 
are produced inside multivesicular bodies in cells and are released after fusing the cell 
membrane (Tao, Guo, & Zhang, 2017). In this review, apoptotic bodies will not be 
considered since there are fewer studies on these particles (Malloci et al., 2019).  
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Figure 4: The classification of extracellular vesicles. EVs are classified as apoptotic 
bodies, microvesicles, or exosomes. Figure taken from (Danielson & Das, 2014).   
 
Molecular Composition of EVs  
 Since EVs are involved in various biological processes such as cell to cell 
communication, inflammation, and metastasis, their molecular properties also vary greatly. 
The majority of EVs are composed of nucleic acids, proteins, or lipids, depending on their 
function and cellular origin.  
EV Nucleic Acid Composition 
There is a range of EV molecular content in literature (Mallochi et al., 2019). In an 
effort to document the variety of molecules contained in EVs, extensive databases such as 
EVpedia and Vesiclepedia exist for reference (Iraci, Leonardi, Gessler, Vega, & Pluchino, 
2016; Kalra et al., 2012; Kim, Lee, Simpson, Lotvall, & Gho, 2015). One category of EV 
composition, specifically exosomes, is nucleic acids such as deoxyribonucleic acid (DNA) 
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and RNA. RNA in EVs was first reported by Ratajczak and colleagues in MVs derived 
from embryonic stem cells (ESCs) (2006). Exosomes can contain messenger RNA 
(mRNA), microRNAs (miRNAs), ribosomal RNA (rRNA), and fragments of transfer RNA 
(tRNA) (Yanez-Mo et al., 2015). Exosomes can contain both long and short RNAs but the 
predominant form contains fewer than 700 nucleotides (Iraci, Leonardi, Gessler, Vega, & 
Pluchino, 2016; Yanez-Mo et al., 2015). Exosomal mRNA may be translated into 
functional proteins once transferred into target cells (Valadi et al., 2007). This transfer of 
intact, functional mRNA into target cells was discovered when human mast cells were 
incubated with mouse mast cell-derived EVs and murine proteins were translated from the 
mRNA transferred by the murine EVs (Valadi et al., 2007). Through this process, 
exosomes containing mRNA may contribute to cell survival by allowing recipient cells to 
internalize the mRNA and translate it into the corresponding protein for differentiation and 
proliferation (Deregibus et al., 2007; Valadi et al., 2007).  
Exosomal transfer of miRNA may have specific physiological importance and 
immunological relevance. miRNA-containing exosomes may evade enzymatic activity and 
avoid degradation to remain in circulation (Yanez-Mo et al., 2015). In doing so, they may 
be able to communicate with neighboring cells allowing the miRNA to alter gene 
expression and phenotype (Charo & Tauv, 2011). The degradation of some miRNA, on the 
other hand, may be involved in lymphocyte activation occurring after vaccination, for 
instance (Yanez-Mo et al., 2015).  
In contrast to the established research on RNA in EVs, the presence of DNA in EVs 
has been less explored. Research shows that EVs can contain single stranded DNA 
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(ssDNA), double stranded DNA (dsDNA) (Thakur et al., 2014), mitochondrial DNA 
(mtDNA) (Guescini, Genedani, Stocchi, & Agnati, 2010), and oncogenic DNA (Lee et al., 
2014). While trafficking mechanisms are understood for RNA, researchers are unsure how 
dsDNA are incorporated into EVs. One proposed mechanism suggests that fragments of 
dsDNA are released into the cytoplasm during the mitotic process. These fragments are 
packaged and subsequently trafficked to specific storage sites (Iraci, Leonardi, Gessler, 
Vega, & Pluchino, 2016). Whatever the mechanism may be, the dsDNA in EVs can provide 
information about the parent cells including their mutational status (Yanez-Mo et al., 
2015). Since dsDNA in EVs can help identify the mutations, it has great potential as a 
translational biomarker. Despite this exciting possibility, more research needs to be 
conducted to completely understand the physiological and pathological role of DNA-
containing EVs.  
EV Protein Components 
EVs can contain a variety of proteins, most of which are considered pan-EV 
proteins (common proteins in EVs). EVs also contain protein modifications specific for 
vesicle release, vesicle localization, and cellular origin. In general, most EVs contain an 
abundance of cytoskeletal proteins, cytosolic proteins, heat shock proteins, and plasma 
membrane proteins (Yanez-Mo et al., 2015). However, classifying which proteins EVs 
contain may be difficult due to differences in isolation methods.  
Since MVs contain elements of the original cells from which they were released, 
most proteins in MVs are residual receptors, nuclear proteins, and cytosolic compartments 
(Malloci et al., 2019). Exosomes contain common proteins that are involved in exosomal 
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biogenesis, exosomal release, and proteins related to endosomal compartments (Malloci et 
al., 2019). The endosomal sorting complex required for transport (ESCRT) is a group of 
proteins necessary for the formation of multivesicular bodies which house the exosomes 
released within the body (Zaborowski, Balai, Breakefield, & Lai, 2015). Exosomes carry 
proteins important related to the ESCRT pathway for biogenesis as well as transportation 
(Zaborowski, Balai, Breakefield, & Lai, 2015). As a general characteristic, exosomes 
usually lack proteins associated with the nucleus, Golgi apparatus, and the endoplasmic 
reticulum (Malloci et al., 2019).  
EV Lipid Composition 
The lipid content may be the most important player in the function of EVs (Yanez-
Mo et al., 2015). MV and exosome lipid bilayers have similar structure but differ in lipid 
composition. The lipid composition of MVs is similar to that of the cell membrane but 
differs in that MVs have no asymmetric distribution of lipids that is usually noted across 
the two layers of the plasma membrane (Hugel, Martinez, Kunzelmann, & Freyssinet, 
2005; Kastelowitz & Yin, 2014; Scott, Pendlebury, & Green, 1984). Moreover, 
phospholipids such as phosphatidylserine and phosphatidylethanolamine are not attached 
to the inner side of the plasma membrane. Instead, these phospholipids are homogenously 
distributed throughout the MVs (Kastelowitz & Yin, 2014; Scott, Pendlebury, & Green, 
1984). Exosomes, in contrast, are abundant in cholesterol, sphingomyelin, and lipid 
ceramide (Kastelowitz & Yin, 2014; Malloci et al., 2019). Lipid ceramide is produced by 
the hydrolysis of sphingomyelin by a specific enzyme within the endosome (Trajkovic et 
al., 2008). The formation of ceramide is important for the creation and sorting exosomes 
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(Trajkovic et al., 2008). The stability of EVs in various cellular environments may result 
from the characteristic lipid distribution of the EV bilayer, which may contribute to 
research that improves liposomal drug delivery systems (Kastelowitz & Yin, 2014; Yanez-
Mo et al., 2015).  
 
EV Biogenesis  
There are two main mechanisms of biogenesis for EVs and are either calcium 
dependent or calcium independent (Gaceb, Martinez, Andriantsitohaina, 2014). MVs are 
released from cells due to an influx of extracellular calcium that causes an increase in 
intracellular cytosolic calcium levels. The heightened calcium concentration inside the cell 
causes the degradation of certain proteins, allowing the membrane to bud and release the 
MV into the extracellular space (Bucki, Bachelot-Loza, Zachowski, Giraud, & Sulpice, 
1998). Exosomes originated from endosomal membrane cellular compartment, the 
multivesicular bodies, that contain particles ready to be released. This release, however, is 
independent of intracellular calcium levels (Abels & Breakefield, 2016; Gaceb, Martinez, 
Andriantsitohaina, 2014).  
The specific mechanisms that cause MVs to be released are unknown; however, 
many studies have demonstrated that the release of MVs are initiated after cellular 
activation or apoptosis (Martinez, Tual-Chalot, Leonetti, & Andriantsitohaina, 2011). 
Certain cytokines including tumor necrosis factor initiates an increase in intracellular 
calcium levels leading to the formation of MVs (Brown, Feairheller, Thakkar, 
Veerabhadrappa, & Park, 2011). The components of MVs depend on multiple factors 
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including the cellular origin and the conditions of cell activation (Bochmann et al., 2014; 
Malloci et al., 2019; Soleti, Lauret, Andriantsitohaina, & Carmen Martinez, 2012). The 
significance of MV composition is that MVs retain elements of the original cell releasing 
the particles (Malloci et al., 2019). The original elements can be ligands, receptors, micro-
RNA, and proteins; thus MVs derived from platelets contain integrins that play a role in 
coagulation and those derived from neutrophils contain proteolytic enzymes that play a 
role in inflammation (Malloci et al., 2019).  
 In contrast to MVs which are released from specific cells, exosomes release can be 
from most cells in the body. Exosomes are also found in body fluids such as blood, saliva, 
urine, seminal fluid, synovial fluid, and cerebrovascular fluid (Urbanelli et al., 2013). 
Exosomes originate from multivesicular bodies, an endosomal compartment, and form as 
intraluminal vesicles with a mixture of proteins, liquids, and cytosolic substance (Abels & 
Breakefield, 2016). They were first described from studies conducted in reticulocytes of 
rats (Harding, Heuser, & Stahl, 1983) and sheep (Pan, Teng, Wu, Adam, & Johnstone, 
1985). Multivesicular bodies usually fuse with lysosomes for degradation or with the cell 
membrane to release the vesicles as exosomes. Since exosomes are formed within an 
endosomal membrane, unlike MVs, their composition differs from their mother cells 
(Malloci et al., 2019). 
 
Functions of EVs in Various Cells  
 Research shows that exosomes derived from ECs, erythrocytes, leukocytes, and 
platelets are increased in patients with CVDs (Hafiane & Daskalopoulou, 2018). This 
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suggests that EVs released from these cells may be involved in the pathophysiology of 
heart conditions, warranting a more in-depth discussion of the implications of EVs derived 
from cells involved in vascular biology.  
Function of EVs Derived from Monocytes and Macrophages 
Monocytes and macrophages both produce EVs in atherosclerotic lesions and 
changes in EVs are found to contribute to CVD (Hafiane & Daskalopoulou, 2018). MVs 
derived from monocytes are hypothesized as being procoagulant since they contain 
substances leading to the formation of thrombin (Owens and Mackman, 2011). In vivo 
studies with mice show that MVs released from monocytes increased atherogenesis 
through the activation of pro-inflammatory macrophages (Hoyer et al., 2012). EVs from 
monocytes are considered essential players in inflammation from the interactions they have 
with a variety of cells including ECs, SMCs, and fibroblasts (Hafiane & Daskalopoulou, 
2018). Specifically, monocyte-derived EVs interact with ECs to induce the expression of 
adhesion molecules which play a major role in the immune response (Jansen, Li, Pfeifer, 
& Werner, 2017). Monocyte-derived EVs can also initiate apoptosis in ECs when 
appropriate (Hromada, Muhleder, Grillari, Redl, & Holnthoner, 2017).  
Similar to monocyte-derived EVs, macrophage-derived EVs can induce apoptosis; 
however, the programmed cell death occurs in vascular SMCs instead of ECs (Hafiane & 
Daskalopoulou, 2018; Yanez-Mo et al, 2015). EVs from macrophages can induce the 
differentiation of naive monocytes into specialized macrophages. Macrophage-derived 
EVs contain major histocompatibility complex class II which allows the vesicle to play a 
role in antigen presentation (Yanez-Mo et al., 2015). There are studies which focus on EVs 
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released by microbially infected macrophages (Bhatnagar, Shinagawa, Castellino, & 
Schorey, 2007; O’Neill & Quah, 2008). In these cases, the infected macrophages cause EV 
content to be altered and promotes the release of EVs that initiate the production of pro-
inflammatory chemokines, cytokines, and miR-223, a substance necessary for myeloid cell 
differentiation and proliferation (Figure 5) (Yanez-Mo et al., 2015). These chemical 
substances can stimulate the migration of other immune cells to the site of infection.  
Figure 5: Microbially infected macrophages release EVs. Macrophages activated by 
microbial infection release EVs which stimulate the release of various cytokines and miR-
223, a substance needed in cell differentiation proliferation. miRNA: microRNA. Figure 
adapted from (Yanez-Mo et al., 2015).  
 
Function of Platelet-Derived EVs 
Platelet-derived EVs have biological functions and play roles in cardiovascular 
pathological processes. Most of the EVs, approximately more than half of all EVs, in 
circulating blood are derived from platelets (Tao, Guo, & Zhang, 2017). The biological 
functions of platelet-derived EVs include regulating inflammation and angiogenesis 
(Zaldivia, McFayden, Lim, Wang, & Peter, 2017). Platelet-derived microvesicles (PMVs) 
have been demonstrated to be both proinflammatory and anti-inflammatory, depending on 
the composition of the cell membrane and substances carried by these particles (Rosinska 
et al., 2019).  
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Generally, the proinflammatory effects of PMVs are due to the store of 
proinflammatory cytokines in their composition or due to their interactions with leukocytes 
and monocytes (Lindemann et al., 2001; Zaldivia, McFayden, Lim, Wang, & Peter, 2017). 
PMVs can attach to leukocytes forming larger aggregates and lead to the activation of 
monocytes. Activated monocytes release inflammatory substances such as interleukin (IL)-
1β and TNF-α (Forlow, McEver, & Nollert, 2000). Specific PMVs which contain IL-1β in 
its composition can promote endothelial dysfunction by causing EC activation through the 
induction of leukocyte adherence (Forlow, McEver, & Nollert, 2000; Zaldivia, McFayden, 
Lim, Wang, & Peter, 2017). In contrast, PMVs can exhibit anti-inflammatory abilities 
(Dinkla et al., 2016). PMVs can inhibit regulatory T cells from becoming pro-inflammatory 
(Dinkla et al., 2016). They accomplish this by binding to a subset of regulatory T cells and 
cease the production of IL-17 and interferon-γ, both of which are needed for T cells to 
exhibit a proinflammatory phenotype (Dinkla et al., 2016). PMVs can also exert anti-
inflammatory effects by altering macrophages and dendritic cells. The presence of PMVs 
cause a decrease in the production of TNF-α and macrophage activation, leading therefore 
to an attenuation of proinflammatory effects (Zaldivia, McFayden, Lim, Wang, & Peter, 
2017).  
PMVs can not only contain proinflammatory cytokines but can also contain 
chemical substances that promote angiogenesis such as VEGF fibroblast growth factor 2 
(Kim, Song, Chung, Lee, & Lee, 2004; Zaldivia, McFayden, Lim, Wang, & Peter, 2017). 
In vitro studies by Brill and colleagues (2005) demonstrated that VEGF contained in PMVs 
can induce angiogenesis. These researchers also showed the angiogenic ability of PMVs in 
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murine models of myocardial infarction (MI). When PMVs were injected into the heart 
muscle of mice, new blood vessels formed in the ischemic hearts (Brill, Dashevsky, Rivo, 
Gozal, Varon, 2005).  
Platelet-derived EVs play many roles in cardiovascular pathology. Specifically, the 
presence of increased PMVs have been seen in patients with CVDs such as acute coronary 
syndrome (George et al., 2015). The increased concentration of PMVs is also associated 
with atherosclerotic plaques in arterial walls (Lukasik et al., 2013). PMVs have been 
implicated in various steps in atherosclerotic plaque development. For instance, PMVs 
transfer miR-223 to target ECs which cause the cells to undergo apoptosis and endothelial-
derived MVs to be released. The MVs released from both cell types act together to increase 
the permeability of the endothelium lining the blood vessels, contributing to one of the 
earliest steps in atherosclerosis (Zaldivia, McFayden, Lim, Wang, & Peter, 2017).  
Function of Endothelial Cell-Derived EVs 
In addition to the monocytes and platelets, EVs that are released by ECs play a 
major role in angiogenesis and inflammation. EVs derived from ECs promote angiogenesis 
by transferring angiogenic substances into recipient cells, leading to the activation of the 
ERK1/2 pathway (Lombardo et al., 2016). The ERK1/2 cascade is involved in many 
cellular processes including cell differentiation, proliferation, and apoptosis (Wortzel and 
Seger, 2011). Through the activation of this pathway, new blood vessels may form via 
paracrine interactions with neighboring ECs.  
ECs are important in the inflammatory process since they recruit monocytes to the 
injured area. Once the monocytes enter the blood vessel, they differentiate into 
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macrophages. Through EV release, ECs can then drive a response to neutralize the 
pathogen or activate other immune cells (Yanez-Mo et al, 2015). Endothelial-derived EVs 
contribute to the inflammatory process in various mechanisms. miRNA in MVs from ECs 
can alter cellular signaling pathways leading to changes in gene expression in recipient 
cells interacting with the EVs (Yanez-Mo et al, 2015). Different miRNAs regulate vascular 
inflammation; one mechanism may be to inhibit the NF-κB transcriptional pathway. This 
pathway is considered proinflammatory since the upstream activation is due to 
proinflammatory substances such as IL-1 and TNF-α (Lawrence, 2009). For instance, miR-
181b inhibits proteins involved in NF-κB activation and inflammation in response to 
proinflammatory stimuli (Sun et al., 2012). EVs play many functions in different cells, 
highlighting their abilities in normal physiological and pathological processes.  
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CHAPTER 4 
EXTRACELLULAR VESICLES IN ATHEROSCLEROSIS PATHOLOGY 
EVs are intimately related to the pathological processes of atherosclerosis. Both 
MVs and exosomes have been linked to the inflammatory processes in the endothelium. 
Specifically, MVs may be involved in the development of early atherosclerotic lesions by 
binding to monocytes and allowing them to enter blood vessels (Hafiane & Daskalopoulou, 
2018). In vitro studies have shown that MVs transfer miRNA-10 to monocytes, thereby 
initiating the NF-κB pathway which leads to monocyte activation (Njock et al., 2015). In 
addition, MVs participate in the migration of activated monocytes into atherosclerotic 
plaques as well as induce the formation of foam cells, both of which increase the 
progression of atherosclerosis (Hafiane & Daskalopoulou, 2018). Exosomes, on the other 
hand, play a proinflammatory role in the development of early atherosclerotic plaques. 
Plasma-derived exosomes have been found to induce inflammation via the NF-κB pathway 
(Ye et al., 2017). Moreover, endothelial derived exosomes lead to increased endothelial 
senescence (Boulanger et al., 2001) which may contribute to vascular dysfunction in 
patients with CVD. Both types of EVs play a role in different developmental steps of 
atherosclerosis. Here, the focus will be on how EVs are inherently involved in the 
pathological development of atherosclerosis.  
  
The Relationship of EVs and Endothelial Dysfunction  
 EVs are involved in one of the earliest processes of atherosclerosis plaque 
development: endothelial dysfunction. Increased blood flow or low shear stress can 
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normally be combated with the release of NO from ECs (Malloci et al., 2019). The released 
NO also regulates the expression of endothelial ATP-binding cassette (ABC) A1 
transporter, which mediates cell membrane modeling (Joyce et al., 2002). NO negatively 
regulates the expression of ABCA1, which is involved in decreasing the amount of MVs 
released from ECs (Malloci et al., 2019). In contrast, low shear stress at vulnerable sites in 
vasculature can contribute to endothelial disturbances. Low shear stress in atherosclerotic 
development causes the activation of ERK1/2 pathway, leading to a decrease in eNOS 
(Malloci et al., 2019). eNOS is constitutively expressed in ECs as an important enzyme for 
NO production (Forstermann, Ning, & Li, 2017). NO produced by eNOS functions in 
vasorelaxation, inhibits platelet aggregation and adhesion, and preventing LDL oxidation 
(Forstermann, Ning, & Li, 2017). Decreased expression of eNOS leads to reduced NO 
levels and consequently lower NO-mediated inhibition of ABCA1. ABCA1 that is more 
active will allow the remodeling of cell membranes and the release of MVs from ECs 
(Malloci et al., 2019).  
MVs are released in pathological conditions not only due to reduced NO-mediated 
inhibition of ABCA1 but also due to low shear stress as the stimuli. Shear stress induced 
ERK1/2 activation not only decreases eNOS but also stimulates MV release from ECs 
(Vion et al., 2013). EC-derived MVs function almost in a feedback loop that further 
decreases eNOS activity and NO production. Once NO production decreases, platelet 
adhesion and LDL oxidation can occur. LDL oxidation reactions cause an increase in 
cytosolic and mitochondrial concentrations of ROS (Maiolino et al., 2013; Malloci et al., 
2019). Uncontrolled production of ROS contribute to endothelial injury occurring in 
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atherosclerosis development (Kattoor, Pothineni, Palagiri, & Mehta, 2017). To examine 
whether MVs play a role in endothelial function, researchers isolated MVs from patients 
with and without vascular diseases such as acute coronary syndrome and intravenously 
injected them into rat aortic rings (Boulanger et al., 2001). They found that MVs from 
pathological conditions induced endothelial dysfunction while MVs isolated from healthy 
subjects did not affect ECs in the rat aortic rings (Boulanger et al., 2001). In the early 
development of atherosclerosis, MVs contribute to the endothelial dysfunction that allows 
for the entry of LDL and immune cells responsible for initiating the growth of the 
atherosclerotic plaque.  
 
The Role of EVs in Vascular Inflammation  
 In addition to their role in endothelial dysfunction, EVs also play a role in the 
subsequent inflammatory cascade following the movement of LDL and monocytes into the 
subendothelial space. LDL accumulated within the tunica intima undergo oxidation 
reactions to become oxLDL, which can cause the release of MVs from monocytes (Malloci 
et al., 2019). oxLDL is also capable of upregulating the chemokine receptor CD36, a 
proinflammatory factor (Rautou et al., 2011). MVs released from monocytes, platelets, and 
even ECs can help in the inflammatory process of atherosclerosis by inducing the release 
of proinflammatory cytokines from leukocytes and ECs (Rautou et al., 2011) as well as 
regulate the adhesion of monocytes to the endothelium before they can enter the tunica 
intima (Malloci et al., 2019). In vitro studies show that MVs can cause the release of 
proinflammatory cytokines IL-6 and IL-8 from ECs (Barry, Pratico, Savani & Fitzgerald, 
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1998; Mesri & Altierir, 1998; Scanu et al., 2008). Both of these cytokines recruit more 
leukocytes to the site of injury and promote the movement of these cells (Rautou et al., 
2011). MVs promote the adhesion of monocytes to the endothelium by inducing the 
expression of intercellular adhesion molecule (ICAM)-1 on ECs (Jansen, Pfeifer, & 
Werner, 2017; Rautou et al., 2011). This change in expression of adhesion proteins 
increases monocytes adherence to the endothelium and the amount that migrates into the 
intima. The change in ICAM-1 expression has been demonstrated in patient samples; those 
with chronic heart failure have higher expression of ICAM-1 (Devaux, Scholz, Hirche, 
Klovekorn, & Schaper, 1997).  
 
EVs in Coagulation and Thrombosis  
 Angiogenesis in the development of atherosclerotic plaques contribute to 
progression of the disease. The number of neovessels sprouting within the plaque makes it 
more vulnerable to intraplaque hemorrhage and plaque rupture (Malloci et al., 2019). As 
MVs are released during the inflammatory cascade, they play a role in thrombus production 
following plaque ruptures. When the atherosclerotic plaque content and MVs are exposed 
to blood, the coagulation cascade is activated leading to potential thrombosis which can 
impede blood flow and cause MI (Badimon et al., 2017). MVs have pro-coagulation 
capabilities due to the negatively charged phosphatidylserine on the surface which allows 
various coagulation factors to bind to them. MVs also express TF, a transmembrane 
receptor that can function to initiate the blood clotting cascade (Badimon et al., 2017). MVs 
derived from endothelial cells can also express von Willebrand factor, a glycoprotein 
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involved in blood clotting (Malloci et al., 2019). These characteristics allow MVs to 
promote the coagulation process.  
 MVs derived from platelets that are released upon endothelial dysfunction can 
enhance the blood clotting process and thrombus formation. Researchers demonstrated that 
PMVs can increase the platelet and fibrin deposition on the blood vessel wall in 
atherosclerosis (Suades, Padro, Vilahur, & Badimon, 2012). They did so by exposing 
atherosclerotic vessels to blood that did and did not contain exogenously injected PMVs 
(Suades, Padro, Vilahur, & Badimon, 2012). Through these experiments, they saw that 
fibrin adhesion were increased (Suades, Padro, Vilahur, & Badimon, 2012). Interestingly, 
a meta-analysis of microvesicles in patients with MI reveals that patients with MI have 
higher levels of MVs compared to healthy subjects (Wang et al., 2017). The circulating 
MVs in these patients were found to increase coagulation and thrombus formation in 
atherosclerosis (Suades, Padro, Vilahur, & Badimon, 2012).  
 
EVs and Vascular Calcification  
 Vascular calcification, an indicator of CVD, occurs in the later stages of 
atherosclerosis progression. EVs exist in atherosclerotic lesions as well as calcified aortic 
valves in humans (Krohn, Hutcheson, Martinez-Martinez, & Aikawa, 2016). The role of 
EVs in atherosclerosis calcification has been well-established. In fact, they have been often 
referred to calcifying extracellular vesicles (CEVs) (Alique, Ramirez-Carracedo, Bodega, 
Carracedo, & Ramirez, 2018). CEVs released from cells such macrophages and SMCs can 
contribute to the formation of calcified atherosclerotic plaques. In a study of human carotid 
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and mouse arteries, researchers found that macrophages released EVs with calcification 
potential as indicated by a high calcium content (New et al., 2013). These EVs contained 
S100A9, a factor implicated in inflammation with pro-thrombotic abilities (Bakhshian Nik, 
Hutcheson, & Aikawa, 2017), and annexin V (Anx5) (New et al., 2013). Annexins are 
cellular proteins involved in SMC derived EV-mediated calcification (New et al., 2013). 
An accumulation of these EVs can lead to mineral deposition within atherosclerotic 
plaques leading to vascular calcification (Bakhshian Nik, Hutcheson, & Aikawa, 2017).  
 SMCs, like macrophages, also release EVs with pro-calcification factors and 
contribute to vascular calcification in atherosclerotic plaques. CEVs from SMCs have 
increased activity of tissue nonspecific alkaline phosphatase (TNAP), an enzyme that 
converts pyrophosphate to phosphate ions which allows the necessary ionic substances for 
mineralization (Bakhshian Nik, Hutcheson, & Aikawa, 2017). CEVs secreted from SMCs 
obtain calcifying abilities through a series of trafficking processes. These processes 
transport sortilin, a specific protein that helps move TNAP into SMC-derived EVs which 
increase their potential to promote calcification (Goettsch et al., 2016). In imaging studies, 
SMC-derived CEVs were found to form microcalcifications in sites with a lower density 
of collagen fibers but form larger calcifications in sites surrounded with a higher density 
of collagen fibers (Hutcheson et al., 2016). In vitro studies where CEVs from SMCs were 
cultured in conditions that mimic atherosclerotic lesions show that CEVs aggregate to form 
microcalcifications and gradually develop into large calcifications (Hutcheson et al., 2016). 
These studies demonstrate the role that EVs from SMCs play in the calcification process 
of atherosclerosis. 
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EVs as a Potential Biomarker for Atherosclerosis  
 EVs contain diverse components as well as functions in various physiological and 
pathological conditions. The roles EVs have in the development and progression of 
atherosclerosis in addition to its structure contribute to its potential as a biomarker. One 
common method to utilize EVs as a potential biomarker involves evaluating the amount of 
EVs in circulation (Dickhout and Koenen, 2018). Many research groups have demonstrated 
a positive correlation between the amount of EVs measured in circulation and CVD. For 
instance, an increase in EV count has been reported in patients with endothelial 
dysfunction, atherosclerosis (Chironi et al., 2006), and those with risk factors for CVD 
such as diabetes (Koga et al., 2006) and hypertension (Preston et al., 2003). Measuring EVs 
released from specific cells of interest could further elucidate EVs’ ability as a biomarker 
for atherosclerosis. For example, one research group investigated and measured the amount 
of EVs released from lymphocytes and SMCs in human participants before and after they 
consumed a Mediterranean diet for one year (Chiva-Blanch et al., 2016). Participants that 
had a cardiovascular event had upregulated EV count while those that did not have an event 
had reduced amount of EVs from lymphocytes and SMCs (Chiva-Blanch et al., 2016). 
Based on this study, the amount of EVs in circulation for individuals is a potential reliable 
diagnostic and monitoring biomarker for cardiovascular events. One of the obstacles in 
using EVs as biomarker will be in determining which cell source to choose from. Currently, 
EV biomarker research focuses cells such as ECs, platelets, dendritic cells, and 
cardiomyocytes (Osteikoetxea, Nemeth, Sodar, Vukman, & Buzas, 2016). Only by 
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determining which source or sources of EVs to best focus on for biomarker research will 
this field show greater promise.  
Many miRNAs in MVs are associated with CVDs (a variety of these are 
summarized in Table 4). Studies in human patients with coronary artery disease (CAD) 
show that MVs contain less miRNA-126 and miRNA-199a, both of which are released 
from ECs and platelets (Chistiakov, Orekhov, & Bobryshev, 2015). miRNA-126 from ECs 
play a proangiogenic role while miRNA-199a increases EC survival (Chistiakov, Orekhov, 
& Bobryshev, 2015). These miRNA indicators may be a potential prognostic biomarker 
for CAD if the levels of miRNAs are determined for individuals in preventative screenings.   
Table 4: Summary of miRNAs associated with CVDs. Specific miRNAs are released 
from cells, each with their own association to cardiovascular diseases. miR: microRNA, 
CAD: coronary artery disease, T2D: type 2 diabetes. Table adapted from (Chistiakov, 
Orekhov, & Bobryshev, 2015).  
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CHAPTER 5 
THERAPEUTIC POTENTIAL OF EXTRACELLULAR VESICLES 
The Favorable Effects of EVs 
 Although EVs exert a pathological effect in the development of atherosclerosis, 
research also shows that EVs can provide favorable effects in physiological processes. EC-
derived MVs can promote endothelial dysfunction; but interestingly, they can also act as a 
messenger to promote endothelial protection and regeneration (Jansen Li, Pfeifer, & 
Werner, 2017). In vitro studies by Hussein and colleagues (2005) demonstrated that EC-
derived MVs can be protective and contribute to EC survival through the transport of 
caspase-3, a proapoptotic enzyme, into MVs. Since a proapoptotic factor is exported from 
ECs into MVs as they are released, ECs may evade apoptosis and survive. In addition to 
this mechanism, another mechanism by which EVs promote endothelial repair and 
regeneration is the use of miRNAs. Different miRNAs transferred into target cells by EVs 
can cause a change in protein expression and consequently lead to repair and regeneration 
of cells (Jansen et al., 2013). Studies conducted by Jansen and colleagues (2013) 
demonstrated that EC-derived MVs can repair cells by transferring miRNA-126 into 
recipient cells. Although miRNA-126 is involved in vascular function, more research is 
needed to explore the downstream processes this may play in. 
 EVs from ECs can promote inflammation in vasculature but they can also cause 
anti-inflammatory effects. EC-derived MVs can have anti-inflammatory potential both in 
vitro and in vivo by transferring a different miRNA to target cells: miRNA-222 (Jansen et 
al., 2015). The transfer of miRNA-222 into ECs causes a decrease in the expression of 
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ICAM-1 (Jansen et al., 2015), an adhesion molecule that aids in the attachment and entry 
of monocytes into the blood vessel wall. With a decrease in ICAM-1 expression in ECs, 
the sustained inflammation that occurs in atherosclerosis development is prevented. 
Another cell type that release anti-inflammatory EVs is mesenchymal stem cells (MSCs). 
MSCs release exosomes that lead to the secretion of a different anti-inflammatory cytokine, 
IL-10 (Jansen Li, Pfeifer, & Werner, 2017).  
 Another contrasting favorable effect that EVs play a role in is atheroprotection. 
Although EVs have been demonstrated to aid the atherosclerotic plaque growth, EVs that 
contain or transfer specific miRNAs can be atheroprotective. In apolipoprotein E knockout 
mice, a commonly used murine model for atherosclerosis, Hergenreider and colleagues 
(2012) found that EC-derived EVs with the expression of the transcription factor krüppel-
like factor 2 (KLF2) can reduce the growth of atherosclerotic plaques in the aorta. They 
also demonstrated that KLF2 regulates the expression of miRNAs 143 and 145. Both of 
these miRNAs are abundant in EC-derived EVs and can control SMC differentiation 
(Hergenreider et al., 2012). Overall, the researchers showed that atheroprotective effects 
of EVs may be mediated through miRNA and the communication between ECs and SMCs.  
 Since EVs are involved in pathological processes but can also exert favorable 
effects in our physiological, the concept of using EVs as a therapeutic tool emerges. 
Currently, the ideas for EV-based disease therapies involve the use of EVs as therapeutic 
agents depending on their cell source, the use of EVs in gene therapy, or engineering EVs 
as delivery tools (detailed in Figure 6).  
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Figure 6: EV therapeutics. The therapeutic potential of EVs will be considered in three 
categories: EVs as the therapeutic agents depending on their cell source, how EVs play a 
role in gene therapy, and how modifying EVs impact their therapeutic potential. EVs: 
extracellular vesicles.  
 
 
Cell-derived EVs as Therapeutic Agents 
The area of CVD stem cell research and stem cell therapy has been plagued by 
fraudulent misconduct by prominent pioneers of the field (Dyer, 2018; Epstein, 2019). 
More now than ever, researchers will need to consider alternative fields  such as the use of 
EVs in disease therapy. The benefits of stem cell therapies has been attributed to paracrine 
factor signaling through the release of EVs (Bei et al., 2017; Gnecchi et al., 2006), 
highlighting the basis for replacing stem cells with EVs in therapies. Although the field is 
not well established, more research into these areas may allow the integration of EVs into 
cardiac intervention therapies in the future.  
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Most of the research conducted involves MSC-derived EVs (Suzuki, Fujita, 
Takahasi, Oba, & Nishimatsu, 2016). Studies of MSC-derived EVs on murine models show 
various effects on cardiovascular pathology (summarized in Table 5). Lai and colleagues 
(2010) determined that MSCs release exosomes that can reduce infarct size in mouse 
models of MI injury. Others have also shown that exosomes can reduce oxidative stress 
and enhance survival in the same mice model (Arslan et al., 2013). In vitro studies by Bian 
and colleagues (2014) demonstrated that human umbilical vein ECs can absorb MSC-
derived EVs and increase proliferation, migration, and angiogenesis in these cells. They 
also performed intramyocardial injections of MSC-derived EVs in a rat model of acute MI 
and found that these injected MSC-EVs could help increase blood flow recovery, reduce 
infarct size, and maintain heart function compared to injections with control solution (Bian 
et al., 2014). Other researchers studying therapeutic effects of EVs in CVD models found 
miRNAs to be implicated. Feng and colleagues found that mouse exosomes released from 
MSCs post-ischemic conditions contained miRNA-22 (Feng, Huang, Wani, Yu, & Ashraf, 
2014). Theses exosomes reduced apoptosis following ischemia by targeting methyl CpG 
binding protein 2 (Feng, Huang, Wani, Yu, & Ashraf, 2014). In a different investigation, 
Yu and colleagues overexpressed (2015) a transcription factor called GATA-4 in rat MSCs. 
They found that the exosomes released from these cells contained an abundance of 
miRNAs, specifically miRNA-19a (Yu et al., 2015). Through the transfer of these miRNA-
19a enriched exosomes into rat cardiomyocytes, cardiac contraction was significantly 
improved and infarct size was attenuated (Yu et al., 2015).  
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Table 5: Studies showing the effects of MSC-derived EVs. Select studies focusing on 
MSC-derived EVs and their effects on cardiovascular disease models are shown below. A 
more detailed explanation of the following studies can be found in the text. ESC: 
embryonic stem cell, MSCs: mesenchymal stem cells, AMI: acute myocardial infarction, 
GATA-4: transcription factor, miR: microRNA, Akt: protein kinase B, GSK3: glycogen 
synthase kinase 3 (protein kinase), c-JNK: c-Jun N-terminal kinase. Table adapted from 
(Suzuki, Fujita, Takahasi, Oba, & Nishimatsu, 2016). 
 
In addition to MSC-derived EVs, ESC-derived EVs can be potential therapeutic 
agents for CVD. Various studies have shown that ESC-derived EVs can cause a variety of 
physiological effects. One study by Khan and colleagues (2015) found that mouse ESC-
derived exosomes led to increased angiogenesis, increased cardiomyocyte survival, and 
less fibrosis following ischemia in the mice model for acute MI. ESC-derived exosomes 
also play a role in regeneration and angiogenesis in mice models. These exosomes are 
abundant in mRNA regulating angiogenic chemical substances such as VEGF and 
fibroblast growth factor 2 (FGF2) (Song et al., 2017). VEGF binds to the VEGF receptor 
on ECs leading to the activation of the PI3K/Akt pathway that promotes cell survival and 
another pathway to promote proliferation and migration (Song et al., 2017). FGF2 works 
with VEGF to promote neovascularization and to maintain ESCs (Song et al., 2017). One 
important factor to consider in cardiac regeneration after MI is the microenvironment 
surrounding the infarcted area. miRNAs from ESC-derived EVs transferred to target cells 
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can produce anti-inflammatory effects by releasing TNF-⍺ and IL-6, both of which are 
anti-inflammatory (Song et al., 2017). By influencing the inflammatory process, the 
microenvironment can be improved leading to a delay in heart failure (Song et al., 2017).  
Researchers have also found that CPC-derived EVs can have therapeutic effects in 
CVD. Several in vivo studies demonstrate the ability of CPC-derived EVs to protect against 
apoptosis and restore cardiac function in murine models. In an initial study, Chen and 
colleagues (2013) demonstrate that murine CPC-derived exosomes injected into the mice 
myocytes following ischemia could decrease apoptosis. This experiment suggest for the 
first time that these exosomes are cardioprotective and represent a potential non-cell 
therapeutic agent (Chen et al., 2013). Other researchers isolated miRNA-210-, miRNA-
132, and miRNA-146a-3p-enriched EVs from human CPCs (Barile et al., 2014). They 
injected these EVs into a rat model for acute MI and demonstrated the same 
cardioprotective effects: enhanced cardiac function, decreased apoptosis, and increased 
angiogenesis (Barile et al., 2014). Similarly, Ibrahim and colleagues (2014) found that 
human CPC-derived exosomes are abundant in miRNA-146a and these exosomes injected 
into a murine model of CVD improved cardiac function.  
EVs released from MSCs, ESCs, CPCs, and various other cells are potential 
therapeutic agents for CVD.  Current research shows that EVs have both detrimental and 
favorable effects. The differences in EV function from a variety of cells should not be 
regarded as experimental inconsistency but rather as proof of the diverse biological abilities 
of EVs (Osteikoetxea, Nemeth, Sodar, Vukman, & Buzas, 2016). If researchers can 
determine the specific cell types that release EVs with favorable effects such as 
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atheroprotective properties rather than focus on the detrimental effects that EVs may have, 
these atheroprotective EVs may be beneficial in the therapy of CVD and atherosclerosis. 
Although the current studies are preclinical, further research is necessary to establish a field 
of EV-based cardiovascular therapy. Not only would the use of these EVs allow us to 
bypass some of the obstacles common in stem cell therapies for CVDs but it also allow for 
an incorporation of precision medicine, leading to improved clinical outcomes. EVs 
represent an expanding research field to help combat the epidemic of CVD and its 
underlying pathology, atherosclerosis.  
 
EVs in Gene Therapy  
In addition to their ability as therapeutic agents, EVs can be a tool in gene therapy. 
Briefly, gene therapy involves the exchange of a defective gene for a corrected gene 
(Darband et al., 2018). One important factor for successful gene therapy is the delivery of 
corrected genes into cells through the use of vectors. A variety of vectors have been used 
including viral vectors, non-viral vectors, and more recently exosomes (Darband et al., 
2018). Exosomes are an excellent candidate in gene therapy for several reasons. Due to 
their size, host biocompatibility due to generation from an individual’s own cells, and the 
ability to transfer genetic material, exosomes can be effective vectors (Zhang, Hu, Zheng, 
& Wang, 2017). In gene therapy, exosomes can be vectors delivering therapeutic agents 
such as miRNAs and small interfering RNAs (siRNAs) (Darband et al., 2018). miRNA and 
siRNA have low stability in circulation, however, the use of exosomes can ensure higher 
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delivery efficiency (Lu et al., 2018). Exosome is stable in circulation but its distribution 
depends on the vasculature (Darband et al., 2018).  
To show that EVs can be potential tools in gene therapy, Wood and colleagues 
(2011) successfully used exosomes to transfer exogenous siRNA across the blood brain 
barrier and silenced specific genes in target cells. In other studies, Momen-Heravi and 
colleagues (2014) demonstrated that they could transport exogenous miRNA-155 
inhibitors to macrophages through the use of B cell-derived exosomes. The miRNA-155 
inhibitors delivered through B cell-derived exosomes caused a decrease in TNF⍺ 
production (Momen-Heravi, Bala, Bukong, & Szabo, 2014). By using EVs in gene therapy, 
an alternative approach for CVD treatment emerges. Although, there are no current 
research examining EV-based gene therapy for atherosclerosis and CVD, its potential 
therapeutic use calls for such investigation.  
 
Engineered EVs as a Delivery Tool  
In relation to their biocompatibility and ability to transport substances between 
cells, EVs not only present as a viable tool for gene therapy but they may also be an 
excellent delivery tool. EVs can deliver not only genetic material to target cells but can 
also drug therapies (Chen, Li, & Liu, 2018). The composition of the membrane surrounding 
EVs allow for the protection against degradation, an advantage when considering the 
storage of drugs for delivery to target cells (Bei et al., 2017). Moreover, EVs are naturally 
stable and since they are produced by cells in physiological processes within the body, they 
can evade the immune system, making them perfect carriers of drug therapies (Bei et al., 
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2017). EV-based therapy has emerged in the field of nanotherapy, which involves the use 
of nanoparticles to deliver drugs to targeted tissues or a location to combat a disease (Lazar 
et al., 2018). Since EVs are released from cells in normal physiological processes, they can 
be used as a delivery tool if the particular EV capable of exerting favorable effects in 
atherosclerosis has been identified. Of course, research in this area is lacking, but growth 
in this field may allow researchers and clinicians to utilize these biologically stable entities 
in drug delivery. Moreover, before EVs can successfully be used as a vehicle for drug 
delivery, modifications can be introduced to help enhance their therapeutic potential. 
Engineered EVs will allow for the incorporation in nanomedicine to treat atherosclerosis 
since EV-based therapy works around issues in cell-based strategies like stress-induced 
necrosis (Armstrong, Holme, & Stevens, 2017).  
Strategies for EV Modifications 
The current synthetic techniques used to enhance the therapeutic capabilities of EVs 
have been used extensively in well-established fields such as cell functionalization, 
processes that alter the cell allowing the development of various functions (Armstrong, 
Holme, & Stevens, 2017; Mout, Moyano, Rana, & Rotello, 2012). Two main approaches 
exist: indirect alteration of EVs or direct EV modification (Mentkowski, Snitzer, Rusnak, 
& Lang, 2018).  
Indirect modifications of EVs involve cell modification, which can be 
accomplished by engineering the cells to biologically produce a specific endogenous 
substance or an exogenous substance that was previously introduced into the system 
(Armstrong, Holme, & Stevens, 2017). There are three main strategies to indirectly alter 
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EVs: genetic engineering of cells, metabolic labelling of the cells leading to EV 
modification, and introducing exogenous material to cells for EV uptake. Genetic 
engineering of cells involves inserting the coding sequences of the protein of interest into 
a transmembrane protein and expressing this in cells using a transfer vector (Mentkowski, 
Snitzer, Rusnak, & Lang, 2018). Through this method, the cells can produce exosomes that 
express the protein of interest in their membranes (Mentkowski, Snitzer, Rusnak, & Lang, 
2018). Various studies were conducted in this manner to modify the proteins expressed on 
EV membranes. One example involves the incorporation of fluorescent proteins into 
transmembrane proteins of EVs. Stickney and colleagues (2016) targeted tetraspanins, 
proteins embedded in EV membranes, and successfully introduced fluorescent reporters 
into their domains via gene transfection in vivo. This and following studies provided 
evidence for proof of concept for indirect cell modification of EVs. In addition to genetic 
engineering, EVs can be modified through metabolic labelling of cells. This method is 
indiscriminate and targets the entire cell through the supplementation of the cell medium 
with exogenous metabolites such as amino acids and lipids (Armstrong, Holme, & Stevens, 
2017). The cells will integrate the exogenous metabolites into the proteome and the 
released EVs will contain metabolically labelled sites (Armstrong, Holme, & Stevens, 
2017). Researchers successfully labelled EVs derived from melanoma cells with azide 
groups using this technique (Wang, Altinoglu, Takeda, & Xu, 2015). The last technique 
for indirect EV modification involves loading exogenous material into cells of interest and 
allowing it to be packaged into EVs for release. However, one major consideration is the 
amount of exogenous material loaded into the cells and how well it binds to the cell. If 
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exogenous material cannot bind securely to the cell, EVs released will not package the 
substance of interest (Armstrong, Holme, & Stevens, 2017). Of the three strategies for 
indirect EV modification, this technique has more extensive limitations.  
In contrast to the indirect cell modification strategies available, EVs can be directly 
modified to enhance their therapeutic potential. These direct modifications can circumvent 
the extensive processes for cell-based technologies and ensure a higher output of modified 
EVs. One strategy in this approach includes modifying the membrane of EVs through 
simple chemical reactions that can form covalent or non-covalent bonds under appropriate 
conditions (Armstrong, Holme, & Stevens, 2017; Mentkowski, Snitzer, Rusnak, & Lang, 
2018). Smyth and colleagues (2014) demonstrated that bioconjugation of substances to the 
surface of EV membranes is possible through simple reactions. The researchers covalently 
bonded alkynes to the amines embedded in EV membrane proteins, with no effects on the 
structure and function of EVs (Smyth et al., 2014). Examples of non-covalent 
modifications of EV membranes include multivalent electrostatic interactions and the 
incorporation of hydrophobic material (Carreira et al., 2016). Multivalent electrostatic 
interactions involve adhering positively-charged species to the negatively-charged groups 
inherent in EV membranes, allowing the production of a positive surface on EVs (Carreira 
et al., 2016). This positively charged EV can more easily bind and absorbed into target 
cells. In contrast, the incorporation of hydrophobic substances in EVs is actually facilitated 
by the lipid composition of EV membranes (Peterson, 2005). EV membranes have higher 
levels of cholesterol and sphingomyelin, allowing an easier migration of lipophilic 
substances into EVs (Armstrong, Holme, & Stevens, 2017). These hydrophobic 
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interactions allow the insertion of a variety of lipophilic drugs (Armstrong, Holme, & 
Stevens, 2017).  
Another approach of direct modification is entrapping material into EVs. To do so, 
the EV membranes must be disrupted to allow drugs and other substances of interest to be 
sequestered inside. Sonification, which tears the EV membranes, and electroporation, 
which temporarily increases the permeability of EV membranes, are two methods that can 
provide this membrane disruption (Mentkowski, Snitzer, Rusnak, & Lang, 2018). The 
augmented permeability resulting from electroporation increases the bioactivity of the 
substances loaded into EVs, leading to more uniformity on the surface membrane and a 
decreased likelihood of being targeted by macrophages for degradation (Mentkowski, 
Snitzer, Rusnak, & Lang, 2018). Overall, these entrapment approaches can increase the 
therapeutic effects of EVs by allowing more uptake of exogenous material or drugs that 
can be delivered in disease therapy.   
Therapeutic Effects and Potential Clinical Applications of Engineered EVs 
Engineered EVs have aspects of their parent cells and nanotechnology, making 
them excellent tools for drug therapies. Since their emergence, EVs have been investigated 
for their ability to be drug delivery tools. One early investigation showing such effects was 
from the work of Sun and colleagues (2010). They successfully incorporated curcumin, an 
anti-inflammatory agent, into exosomes without inducing toxicity or off-target effects (Sun 
et al., 2010). Moreover, using murine models of lipopolysaccharide-induced brain 
inflammation, engineered exosomes with encapsulated curcumin were found to protect the 
mice from the inflammation (Zhuang et al., 2011). Although these studies are preclinical, 
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the investigations are promising. Significant work is necessary to incorporate this 
nanotechnology in clinical use. 
The idea of using exosomes in clinical applications; however, is not new. In fact, 
exosome-based therapies have been approved for several clinical studies, mostly for cancer 
treatments. For instance, in one study researchers purified exosomes from cultures of 
patients with metastatic melanoma (Escudier et al., 2005). The exosomes obtained were 
inserted with melanoma antigen and administered to the patients as a therapeutic 
vaccination (Escudier et al., 2005). The patients tolerated the administrations for up to 21 
months, demonstrating the feasibility and safety of exosome-based technology. Another 
phase I clinical trial involving exosomes and patients with advanced non-small cell lung 
cancer was conducted in the same year (Morse et al., 2005). Exosomes derived from 
dendritic cells were loaded with tumor antigens and given to patients (Morse et al., 2005). 
The researchers found that there was a low immune response following administration, 
demonstrating the safety and feasibility of EV-based interventions (Morse et al., 2005). In 
both early clinical studies, researchers modified the exosomes obtained from patient cells 
and loaded antigens into them. The same concept may be applied in clinical applications 
to introduce exogenous material or drug therapies into the exosomes for engineered EV-
based therapy.  
 
Recent Preclinical Studies of EVs and CVDs  
An important step in furthering the field of EV-based therapeutics involves 
exploring how modified EVs can be beneficial in preclinical investigations of 
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cardiovascular therapy. Despite the lack of research for EV-based therapy in 
atherosclerosis, there are important investigations involving EVs and CVD that needs to 
be evaluated.  
In a preclinical investigation involving MSC-derived exosomes, Sun and 
colleagues (2018) show that intravenous administration of exosomes can improve cardiac 
function in a murine model of dilated cardiomyopathy. Dilated cardiomyopathy is one of 
the most common consequences of inflammation occurring in myocytes (Sun, Shan, Wei, 
& Xu, 2018). To establish a murine model for dilated cardiomyopathy, the researchers 
injected mice with doxorubicin, a chemotherapeutic drug. They isolated MSCs from the 
mice and extracted exosomes via ultracentrifugation. The researchers then intravenously 
injected the mice with MSC-derived exosomes or a phosphate-buffered saline (PBS) 
control solution and measured cardiac function via echocardiography. Through their 
examination, they found that mice with dilated cardiomyopathy injected with MSC-derived 
exosomes had improved cardiac function and decreased cardiac dilation (Sun, Shan, Wei, 
& Xu, 2018). They also found that the injected MSC-derived exosomes suppressed the 
inflammatory response elicited by dilated cardiomyopathy and attenuated the apoptotic 
processes of cardiomyocytes (Sun, Shan, Wei, & Xu, 2018). By modifying the mice 
exosomes, the researchers highlighted the ability of exosomes to mediate the detrimental 
effects of inflammation in cardiovascular environment.  
In a separate preclinical investigation, Wang and colleagues (2018) modified EVs 
from MSCs in an attempt to enhance their therapeutic potential. These researchers isolated 
MSCs from C57BL/6 mice, a commonly used model for mutant mice (Mekada et al., 
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2009). They utilized molecular cloning technology and lentiviral packaging to incorporate 
an ischemic myocardium-targeting peptide (IMTP) into the exosomes (Kanki et al., 2011; 
Wang et al., 2018). IMTP is a peptide that targets and binds preferentially to ischemic 
tissues in vivo (Kanki et al., 2011). In vitro, they found that exosomes containing this 
peptide could be internalized by hypoxic cells more efficiently than exosomes without this 
peptide (Wang et al., 2018). Moreover, when they administered the exosomes that express 
IMTP to the murine model for MI (schematic shown in Figure 7), they found that the 
exosome treatment inhibited the inflammatory response, decreased myocardial apoptosis, 
reduced the size of myocardial infarct and preserved cardiac function (Wang et al., 2018). 
The researchers also found that exosomes containing IMTP increased the density of 
capillaries in the ischemic border zone compared to mice without this administration 
(Wang et al., 2018). Overall, this investigation demonstrated that engineered exosomes 
containing IMTP targets the ischemic areas in MI and can play an important role in therapy. 
This preclinical study also shows clinical implications, specifically that MSC-derived 
exosomes with this specific peptide that can target the ischemic myocardial tissue can be 
used as a delivery tool for therapeutic agents.  
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Figure 7: Schematic of exosome therapy. Wang and colleagues collected MSCs from the 
bone marrow of mice and transduced the expression of the ischemic myocardium-targeting 
peptide. The cells produced exosomes that expressed this peptide and these exosomes were 
isolated and purified. Exosomes containing the ischemic myocardium-targeting peptide 
were administered to mice modeling myocardial infarction and investigated for various 
cardiovascular properties. Figure taken from (Wang et al., 2018). 
 
 In addition to these preclinical studies looking at MSCs, other researchers examined 
CPC-derived exosomes. Myocardial infarcted tissue has increased expression of stromal 
cell-derived factor 1 (SDF-1ɑ), a chemokine that is common in ischemic tissues (Ciullo et 
al., 2019). This chemokine binds to CXCR4 receptor, acting as a chemoattractant for cells 
such as progenitor cells (Ciullo et al., 2019). Early this year, Ciullo and colleagues (2019) 
demonstrated that their modification of exosomes improved the efficacy of the 
cardioprotective effects. They isolated exosomes from CPCs of rats and overexpressed the 
CXCR4 receptor on these cells (Ciullo et al., 2019). Overexpression of these receptors in 
the CPCs allowed the expression of CXCR4 on the released exosomes. By injecting these 
CXCR4 enriched exosomes derived from CPCs intravenously into rats, the researchers 
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showed that these exosomes were more available in the ischemic hearts and significantly 
reduced the infarct size. Although different than the previous investigation, once again the 
therapeutic potential of engineered EV for CVD is highlighted.   
These recent preclinical investigations all involve the isolation of the EV of interest 
and their injection back into the animal model. A similar approach may be adapted and 
potentially used for human investigations (Figure 8). For instance, cells of interest, such 
as leukocytes, can be obtained through apheresis, a process that separates the cells from 
peripheral blood. These cells can be given time to differentiate and grow and be modified 
via the transfection of DNA into the cells or loading agents into the cell. After the 
exogenous agents or therapeutic material is incorporated into exosomes, these exosomes 
can be isolated upon release from the cells. These modified exosomes can then be 
administered to the patient. In another approach, after apheresis of the cells of interest from 
the patient, naive exosomes can be isolated from the cells and be directly modified through 
the loading of exogenous material or drug therapies. From this approach, these exosomes 
can be administered to the patient for effect (Batrakova & Kim, 2015).  
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Figure 8: Engineering EVs for clinical applications. Engineered EVs can be 
implemented in clinical applications following processes to enhance their therapeutic 
potential. Cells of interest can be obtained and isolated from patients’ peripheral blood 
through apheresis. Following apheresis, cells can be cultured, differentiated, and 
transfected with exogenous DNA or loaded with therapeutic agents. Once the genetic or 
therapeutic material is incorporated into exosomes, these exosomes can be isolated and 
purified. These modified exomes can be administered to patients for therapeutic effects. In 
contrast, once cells of interest are obtained, separated, and differentiated from patients’ 
peripheral blood, naive exosomes can be isolated from these cells. Researchers can then 
modify the naive exosomes by loading them with therapeutic agents. These drug-loaded 
exosomes can also be administered to patients for potential therapeutic effects. Figure 
adapted from (Batrakova & Kim, 2015).  
 
Although this has not been attempted for CVD and atherosclerosis treatment, such 
a model exists. Perhaps once researchers successfully identify and isolate EVs that can 
exert atheroprotective effects from both healthy and disease populations, their use can be 
applied in clinical settings. Atherosclerosis is a chronic condition that develops slowly over 
time and EVs are implicated in the disease progression. If EVs can be used effectively and 
successfully both as a biomarker to monitor disease status and a therapeutic agent, perhaps 
an alternative treatment may emerge. Early detection of pathophysiological events like the 
maintenance of the inflammatory cascade in atherosclerosis with EVs as an indicator and 
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successfully using engineered EVs that can exert anti-inflammatory effects, for example, 
may allow us to delay the progression of atherosclerosis. Again, extensive research is 
necessary before EVs can be considered as an appropriate biomarker for atherosclerosis. 
Likewise, significant growth in the area of EVs-based therapeutics and engineered 
exosomes is necessary before they can be used effectively as therapy.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS  
 EVs play important roles in physiological and pathological processes. Emerging 
evidence indicates that they also can be used for treatments in CVD.  There are several 
obstacles in EV research that needs to be explored before the field can advance. One of the 
major limitations of EV research involves the lack of standardization of EV isolation. The 
isolation and purification methods for EVs differ depending on the donor cells they are 
derived from as well as between various research groups (Jansen, Li, Pfeifer, &Werner, 
2017). The conventional and most commonly used method for EV isolation is 
centrifugation followed by ultracentrifugation. Although this technique is effective in 
isolating EVs from donor cells, it is a long procedure that often has low output, both of 
which can limit applications in clinical studies (Jansen, Li, Pfeifer, &Werner, 2017). In 
clinical procedures, size exclusion chromatography and affinity chromatography can be 
used to isolate EVs. Size exclusion chromatography has high producibility but can become 
contaminated easily. Affinity chromatography, on the other hand can isolate populations 
of EVs with high purity (Jansen, Li, Pfeifer, &Werner, 2017). This method, however, is 
costly and limits its applicability. The development and standardization of EV isolation is 
necessary in the advancement of EV-based technology and eventual use as disease therapy. 
More efforts are needed in the future to increase the producibility and purity of EVs across 
various research groups, reaching a standardized protocol for clinical applications.  
 Another important limitation in EV research involves the processing of EVs after 
cellular uptake in target cells. We know that EVs are involved in biological processes in a 
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variety of diseases and have witnessed their abilities to deliver therapeutic agents and 
exogenous genetic material to recipient cells in vitro and in vivo. However, the obstacle in 
the advancement of this field is the lack of research in understanding how incorporated 
EVs are processed (Jansen, Li, Pfeifer, &Werner, 2017). In an attempt to address this issue, 
fluorescence labelling of vesicles can be applied to see how material transferred by EVs to 
target cells are distributed and processed. Although plausible, this technique requires many 
improvements before effectively performed. In addition to the processing mechanisms 
inside target cells, another unclear area that needs more research is the offset side effects 
that may result from EV-based therapy. The introduction of EVs in both animals and 
humans have shown beneficial results; however, uncertainties in whether adverse effects 
may result with long term administration remain (Amosse, Martinez, & Le Lay, 2017). 
More research in this direction will further our knowledge about the biodistribution of EVs 
and how they affect animal and human tissues in the long run. 
 EVs play important roles in cellular communication and can deliver material from 
parent cells to recipient cells. EVs are made of a variety of components, making them a 
diverse group of particles with varied functions. Not only are they important in the 
physiological processes, they are important in pathological processes of diseases. EVs are 
involved in the development of atherosclerosis, the underlying pathology that leads to 
CVD. EVs play an important role in almost all of the steps in atherosclerosis development 
and progression. Since its role in pathology has been established, the exploration of EV-
based therapy in atherosclerosis and other CVDs have emerged. Despite this, the field of 
EV research requires extensive expansion before their risks and benefits can be objectively 
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determined for clinical applications. Currently, most of the recent studies remain in the 
preclinical phase for CVD therapy. To approach precision medicine for CVD, researchers 
can consider the use of EVs as therapeutic agents or tools in clinical investigations. Based 
on the success for EV-based therapy in cancer, there is significant potential for CVD. 
Extensive research is needed to advance the field of EV-based therapy for atherosclerosis 
and CVD before clinicians and researchers can combat the growing epidemic and achieve 
precision medicine. 
 
 
Figure 9: EVs driving progress in CVD precision medicine. On the left, the current 
standard approach for treating CVD, and atherosclerosis specifically, involves lifestyle 
modifications and the use of pharmacological treatments. As the field of EV research 
expands, the treatment of atherosclerosis and CVD will soon incorporate EV-based 
precision medicine. EV-based therapy may be able to address the obstacles of current 
atherosclerosis and CVD treatment. 
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